Intranasal Human Milk for Intraventricular Hemorrhage

Status Active, not recruiting

Clinical Trial Summary

Intraventricular hemorrhage (IVH) is a leading cause of brain injury in infants born before term. Severe IVH, which occurs nearly exclusively in very preterm infants (born before 32 weeks gestation) who are already at risk of neurodevelopmental delays and cerebral palsy at baseline, results in a ~5 times higher risk of death or moderate-severe neurodevelopmental impairment, as well as short-term morbidities in the neonatal intensive care unit (NICU). Infants with grade I and II IVH, although less severe than the higher grades of IVH, also have a higher risk of death or moderate to severe neurodevelopmental impairment compared to infants with a normal head ultrasound. Outcomes are worsened by the fact that the brains of these preterm infants are not fully developed, so the progenitor cells that would later differentiate and mature are damaged, resulting in hypomyelination and gray matter loss that are associated with poor neurodevelopmental outcomes. There is no available therapy to treat the IVH or resultant brain injury, other than symptomatic management for resultant post-hemorrhagic hydrocephalus with lumbar punctures and temporary or permanent shunts, which have significant risks on their own. This is a phase I trial to determine whether fresh intranasal human milk (HM) can be safely delivered as stem cell therapy to preterm IVH patients within a 3-hour window from HM expression and to identify signals which would indicate whether intranasal HM stimulates the repair of damaged brain tissue. Outcomes will be compared to HM fed historical IVH controls. Recruitment will take place in tertiary care NICUs in Toronto, which care for the highest proportion of very preterm infants with IVH in Canada. These NICUs have already adopted a common protocolized approach to manage severe IVH and post-hemorrhagic hydrocephalus with intensive monitoring, early symptomatic management, and detailed prospectively collected IVH data.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04225286
Study type	Interventional
Source	The Hospital for Sick Children
Contact
Status	Active, not recruiting
Phase	N/A
Start date	March 11, 2020
Completion date	December 2023

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT04506619` - Safety and Efficacy Outcomes Following Previously Administered Short-Term Treatment With SHP607 in Extremely Premature Infants
Recruiting	`NCT04189471` - Recovery After Cerebral Hemorrhage
Recruiting	`NCT06043050` - PRedicting OutcomeS in Preterm nEonates With thromboCyTopenia (PROSPECT)
Terminated	`NCT04178746` - PRONTO: Artemis in the Removal of Intraventricular Hemorrhage in the Hyper-Acute Phase
Not yet recruiting	`NCT06045130` - PUFAs in Preterm Infants
Completed	`NCT02400697` - Placental Transfusion Project for Preterm Infants	N/A
Recruiting	`NCT05113381` - The Purpose of This Study is to Determine Whether CerebroFlo™ EVD Catheter is Effective During the Treatment of IVH	N/A
Not yet recruiting	`NCT06429332` - International Care Bundle Evaluation in Cerebral Hemorrhage Research	Phase 4
Recruiting	`NCT03754439` - Minimising the Adverse Physiological Effects of Transportation on the Premature Infant
Recruiting	`NCT05118997` - Active Removal of IntraCerebral Hematoma Via Active Irrigation	N/A
Recruiting	`NCT01098890` - Intraventricular Tissue Plasminogen Activator (tPA) in the Management of Aneurysmal Subarachnoid Hemorrhage	Phase 2
Recruiting	`NCT05568264` - Effects of a Physical Therapy Intervention on Motor Delay in Infants Admitted to a Neonatal Intensive Care Unit	N/A
Terminated	`NCT04538079` - Non-invasive Objective Assessment of Hemodynamics in Preterm Neonates
Completed	`NCT00809055` - MRI and Neurodevelopment in Preterm Infants Following Administration of High-Dose Caffeine	Phase 4
Completed	`NCT00197392` - Comparative Infection Rates for the Codman BACTISEAL TM External Ventricular Drainage (EVD) System	Phase 4
Completed	`NCT03110887` - Monitoring Outcome in Neonatal Thrombocytopenia	N/A
Recruiting	`NCT06256939` - Therapy BRIDGE (Bringing Real-Time Instruction Via Developmental and Gestationally-appropriate Education/Coaching) Program: A Pilot Study	N/A
Recruiting	`NCT03253263` - A Clinical Efficacy and Safety Study of OHB-607 in Preventing Bronchopulmonary Dysplasia in Extremely Premature Infants	Phase 2
Not yet recruiting	`NCT02394678` - Rheolytic Thrombectomy For Adult Intraventricular Haemorrhage	N/A
Completed	`NCT00875758` - Optimizing Treatment of Post-hemorrhagic Ventricular Dilation in Preterm Infants	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.